Vitamin K Deficiency Bleeding

Categories: Blood diseases, Gastrointestinal diseases, Metabolic diseases

Aliases & Classifications for Vitamin K Deficiency Bleeding

MalaCards integrated aliases for Vitamin K Deficiency Bleeding:

Name: Vitamin K Deficiency Bleeding 12 15
Vitamin K Deficiency 12 54 43
Deficiency of Vitamin K 12 32
Vitamin K Deficiency Hemorrhagic Disease 12
Vitamin K 42


External Ids:

Disease Ontology 12 DOID:11249
ICD9CM 34 269.0
MeSH 43 D014813
NCIt 49 C99108
SNOMED-CT 67 52675005
ICD10 32 E56.1
UMLS 71 C0042880

Summaries for Vitamin K Deficiency Bleeding

MedlinePlus : 42 Vitamins are substances that your body needs to grow and develop normally. Vitamin K helps your body by making proteins for healthy bones and tissues. It also makes proteins for blood clotting. If you don't have enough vitamin K, you may bleed too much. Newborns have very little vitamin K. They usually get a shot of vitamin K soon after they are born. If you take blood thinners, you need to be careful about how much vitamin K you get. You also need to be careful about taking vitamin E supplements. Vitamin E can interfere with how vitamin K works in your body. Ask your health care provider for recommendations about these vitamins. There are different types of vitamin K. Most people get vitamin K from plants such as green vegetables, and dark berries. Bacteria in your intestines also produce small amounts of another type of vitamin K.

MalaCards based summary : Vitamin K Deficiency Bleeding, also known as vitamin k deficiency, is related to hereditary combined deficiency of vitamin k-dependent clotting factors and protein c deficiency. An important gene associated with Vitamin K Deficiency Bleeding is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Metabolism of proteins and Response to elevated platelet cytosolic Ca2+. The drugs Acenocoumarol and fluindione have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and kidney, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A nutritional deficiency disease that is characterized by easy bleeding due to an inability to form blood clots caused by vitamin K deficiency, occurs most commonly in newborns, and has material basis in deficiency of vitamin K secondary to liver prematurity, lack of vitamin K in a breastmillk diet, largely sterile gut, malabsorption, diarrhea, chronic illness, menorrhagia, chronic kidney disease, and some medications.

Wikipedia : 74 Vitamin K deficiency results from insufficient dietary vitamin K1 or vitamin K2 or... more...

Related Diseases for Vitamin K Deficiency Bleeding

Diseases related to Vitamin K Deficiency Bleeding via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 581)
# Related Disease Score Top Affiliating Genes
1 hereditary combined deficiency of vitamin k-dependent clotting factors 34.5 VKORC1 GGCX
2 protein c deficiency 31.8 SERPINC1 F9 F2
3 factor x deficiency 31.7 F9 F7 F3 F2
4 protein s deficiency 31.6 SERPINC1 PROS1 F8 F3 F2
5 hemophilia b 31.0 SERPINC1 F9 F8 F7 F3 F2
6 factor vii deficiency 30.9 SERPINC1 F9 F8 F7 F3 F2
7 atrial fibrillation 30.7 VKORC1 SERPINC1 F3 F2
8 hematocele of tunica vaginalis testis 30.6 F2 AFP
9 urolithiasis 30.5 GGCX F2 BGLAP
10 hemopericardium 30.5 F3 F2
11 prothrombin deficiency 30.4 SERPINC1 GGCX F9 F8 F7 F3
12 thrombophilia due to thrombin defect 30.3 SERPINC1 F8 F3 F2
13 calciphylaxis 30.3 PTH MGP
14 hemophilia 30.3 F9 F8 F7
15 antiphospholipid syndrome 30.2 SERPINC1 F3 F2
16 alpha-1-antitrypsin deficiency 30.1 SERPINC1 F2 AFP
17 analbuminemia 30.1 F3 F2
18 liver cirrhosis 30.1 SERPINC1 F3 F2 AFP
19 mitral valve stenosis 30.1 SERPINC1 F3 F2
20 prothrombin deficiency, congenital 30.1 SERPINC1 F2
21 pseudoxanthoma elasticum 30.1 VKORC1 MGP GGCX
22 hyperphosphatemia 30.1 PTH MGP BGLAP
23 heparin-induced thrombocytopenia 30.1 SERPINC1 F3
24 active peptic ulcer disease 29.9 F7 F3 F2
25 peripheral vascular disease 29.8 SERPINC1 F3 F2
26 intracranial embolism 29.8 SERPINC1 F3 F2
27 thrombocytosis 29.7 SERPINC1 F3 F2
28 hypervitaminosis a 29.7 PTH BGLAP
29 purpura 29.7 SERPINC1 PROS1 F3 F2
30 retinal vascular occlusion 29.7 VKORC1 SERPINC1 F2
31 portal vein thrombosis 29.7 SERPINC1 F7 F2 AFP
32 hemolytic-uremic syndrome 29.5 SERPINC1 F3 F2
33 pulmonary embolism 29.5 SERPINC1 PROS1 F9 F8 F3 F2
34 hemophilia a 29.5 F9 F8 F7 F3
35 esophageal varix 29.5 SERPINC1 F3 F2 AFP
36 cardiac tamponade 29.5 F9 F8 F7 F3 F2
37 post-thrombotic syndrome 29.5 SERPINC1 F8 F3 F2
38 bilirubin metabolic disorder 29.5 F9 F3 F2 AFP
39 patent foramen ovale 29.4 SERPINC1 F3 F2
40 blue toe syndrome 29.4 SERPINC1 F3 F2
41 lemierre's syndrome 29.4 SERPINC1 F3 F2
42 cerebrovascular disease 29.4 VKORC1 F8 F7 F2
43 antithrombin iii deficiency 29.4 SERPINC1 F3 F2
44 nephrolithiasis 29.4 PTH MGP F2 BGLAP
45 vascular disease 29.4 SERPINC1 PTH MGP F8 F3 F2
46 carotid artery thrombosis 29.3 SERPINC1 F3
47 retinal vein occlusion 29.3 VKORC1 SERPINC1 F3 F2
48 disseminated intravascular coagulation 29.2 SERPINC1 F9 F7 F3 F2
49 hypothyroidism 29.2 F9 F8 F3 F2 BGLAP
50 hemorrhagic disease 29.1 SERPINC1 F9 F8 F7 F3 F2

Graphical network of the top 20 diseases related to Vitamin K Deficiency Bleeding:

Diseases related to Vitamin K Deficiency Bleeding

Symptoms & Phenotypes for Vitamin K Deficiency Bleeding

MGI Mouse Phenotypes related to Vitamin K Deficiency Bleeding:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 F2 F3 F7 F9 GAS6 GGCX
2 hematopoietic system MP:0005397 9.93 BGLAP F2 F3 F8 F9 GAS6
3 homeostasis/metabolism MP:0005376 9.8 AFP BGLAP F2 F3 F7 F8
4 mortality/aging MP:0010768 9.47 AFP F2 F3 F7 F8 F9

Drugs & Therapeutics for Vitamin K Deficiency Bleeding

Drugs for Vitamin K Deficiency Bleeding (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
2 fluindione Approved, Investigational Phase 4 957-56-2
Ticagrelor Approved Phase 4 274693-27-5 9871419
Acetaminophen Approved Phase 4 103-90-2 1983
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
6 Bemiparin Approved, Investigational Phase 4 91449-79-5
Telithromycin Approved Phase 4 191114-48-4 70789201 5462516
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Ofloxacin Approved Phase 4 82419-36-1 4583
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Dronedarone Approved Phase 4 141625-93-6, 141626-36-0 154087
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Apixaban Approved Phase 4 503612-47-3 10182969
Protein C Approved Phase 4
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
Coumarin Experimental Phase 4 91-64-5 323
20 Prasugrel hydrochloride Phase 4 389574-19-0
21 Vitamin K 2 Phase 4
22 Hypolipidemic Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Anticholesteremic Agents Phase 4
25 Antimetabolites Phase 4
26 Cytochrome P-450 Enzyme Inhibitors Phase 4
27 Cholestyramine Resin Phase 4
28 Gastrointestinal Agents Phase 4
29 Antacids Phase 4
30 Anti-Ulcer Agents Phase 4
31 Proton Pump Inhibitors Phase 4
32 polysaccharide-K Phase 4
33 Erythromycin Estolate Phase 4
34 Erythromycin stearate Phase 4
35 Cyclosporins Phase 4
36 Erythromycin Ethylsuccinate Phase 4
37 protein S Phase 4
38 Protamines Phase 4
39 Fibrinolytic Agents Phase 4
40 calcium heparin Phase 4
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
Prilocaine Approved Phase 2, Phase 3 721-50-6 4906
Povidone Approved Phase 2, Phase 3 9003-39-8
Povidone-iodine Approved Phase 2, Phase 3 25655-41-8
Sodium citrate Approved, Investigational Phase 3 68-04-2
Tranexamic Acid Approved Phase 2, Phase 3 1197-18-8 5526
Verapamil Approved Phase 2, Phase 3 52-53-9 2520
Quinidine Approved, Investigational Phase 2, Phase 3 56-54-2 441074
Polidocanol Approved Phase 2, Phase 3 9002-92-0

Interventional clinical trials:

(show top 50) (show all 526)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
2 Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal With 4F-PCC Unknown status NCT03473132 Phase 4 four factor prothrombin complex concentrate
3 APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation Unknown status NCT02789917 Phase 4
4 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
5 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
6 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
7 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
8 The Effect of Vitamin K Supplementation on Glucose Metabolism Completed NCT00960973 Phase 4 Menatetrenone;Placebo
9 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
10 The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial Completed NCT02610933 Phase 4 rivaroxaban
11 Multicenter, Prospective Randomized Trial on the Use of Prothrombin Complex and Fresh Frozen Plasma in Patients With Intracerebral Hemorrhage Related to Vitamin K Antagonists Completed NCT00928915 Phase 4 Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
12 Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD Completed NCT02046460 Phase 4 Acetylsalicylic acid;Vitamin K antagonist
13 An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention Completed NCT02415400 Phase 4 Apixaban;vitamin K antagonist;Acetylsalicylic acid
14 Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY) Completed NCT03091569 Phase 4
15 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
16 The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT Completed NCT02376803 Phase 4 Warfarin
17 D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized "Prolong" Study Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
18 A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
19 Phase IV Study on the Efficacy of PPSB-SD and VP-VI in Patients Using Oral Anticoagulant Therapy and Undergoing Acute Cardiac Surgery With a Cardiopulmonary Bypass Completed NCT00151853 Phase 4 PPSB-SD
20 An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation Completed NCT02227550 Phase 4 Vitamin K antagonist;Apixaban
21 Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism Completed NCT00711308 Phase 4 tinzaparin;acenocoumarol
22 Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis Completed NCT00689520 Phase 4 tinzaparin;acenocoumarol
23 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium Completed NCT02376010 Phase 4 rivaroxaban;Warfarin
24 Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
25 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
26 A Prospective, Randomized Study of Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal at a Large Tertiary Care Medical Center Completed NCT03064035 Phase 4 4-factor prothrombin complex concentrate (4FPCC)
27 Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation Completed NCT01339819 Phase 4 Dabigatran;Phenprocoumon
28 the Post Operative Pericardial Effusion (POPE) Treatment Study Completed NCT00247052 Phase 4 diclofenac;diclofenac;matching placebo
29 An International, Multi-centre, Prospective, Open-Label, Non-Randomised, Uncontrolled Study to Assess the Efficacy and Safety of Prothromplex Total in Oral Anticoagulant Reversal in Patients With Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X) Completed NCT01159210 Phase 4
30 Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants Completed NCT02720328 Phase 4
31 Comparison of the Effect of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes Using the Validated Cooperstown 5+1 Cocktail Completed NCT00164112 Phase 4 Cooperstown 5+1 alone;Azithromycin plus Cooperstown 5+1;Telithromycin plus Cooperstown 5+1;Levofloxacin plus Cooperstown 5+1
32 Reversion of the Anticoagulant Effect of the New Antithrombotic Agents Anti-Xa and Anti IIa by Specific and Non-specific Haemostatic Drugs,: an Ex-Vivo Study in Healthy Volunteers Completed NCT01210755 Phase 4 Rivaroxaban, Dabigatran;Dabigatran; Rivaroxaban
33 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban
34 Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study Completed NCT02559856 Phase 4 Apixaban;Rivaroxaban
35 Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
36 EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin Completed NCT01119300 Phase 4
37 EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon Completed NCT01119274 Phase 4
38 EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol Completed NCT01119261 Phase 4
39 Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? Completed NCT02876354 Phase 4 Menaquinone
40 Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study Completed NCT02567461 Phase 4 Edoxaban 60 mg;Edoxaban 30 mg;Clopidogrel 75 mg;Aspirin 81 mg
41 Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study Completed NCT01962545 Phase 4 OAC alone
42 Finding the Optimal Dose of Rivaroxaban in Hemodialysis Patients Completed NCT02047006 Phase 4 Rivaroxaban 10 mg
43 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
44 PerMIT: Warfarin : A Prospective Randomized Controlled Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy Completed NCT00993200 Phase 4 Warfarin
45 A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of Coagulation Activation in Venous and Shed Blood in Healthy Male Subjects Completed NCT01812200 Phase 4 Dabigatran, Ticagrelor, ASA;Rivaroxaban, Ticagrelor, ASA;Phenprocoumon, Ticagrelor, ASA
46 Randomized Trial of Uninterrupted Versus Interrupted Anticoagulant Therapy in Patients Undergoing Cardiac Pacing Device Implantation Completed NCT00479362 Phase 4 Warfarin;Aspirin
47 Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs Completed NCT00438230 Phase 4 Warfarin
48 Absence of Residual Vein Thrombosis After an Episode of Unprovoked Deep Vein Thrombosis: Short-Term Anticoagulation is Safe. Completed NCT00623987 Phase 4 warfarin accordingly INR value
50 Therapeutic Equivalence Between Branded and Generic Warfarin Sodium Tablets in Adult Patients With Atrial Fibrillation in Brazil - Crossover Randomized Controlled Equivalence Trial Completed NCT02017197 Phase 4 Marevan®;generic warfarin #1;generic warfarin #2

Search NIH Clinical Center for Vitamin K Deficiency Bleeding

Cochrane evidence based reviews: vitamin k deficiency

Genetic Tests for Vitamin K Deficiency Bleeding

Anatomical Context for Vitamin K Deficiency Bleeding

MalaCards organs/tissues related to Vitamin K Deficiency Bleeding:

Bone, Liver, Kidney, Heart, Testes, Breast, Skin

Publications for Vitamin K Deficiency Bleeding

Articles related to Vitamin K Deficiency Bleeding:

(show top 50) (show all 1118)
# Title Authors PMID Year
Laboratory assessment of vitamin K status. 42 61
31862867 2020
Effect of vitamin K1 on survival of patients with chronic liver failure: A retrospective cohort study. 42
32221088 2020
Exploratory analysis of covariation of microbiota-derived vitamin K and cognition in older adults. 42
31518386 2019
Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging? 54 61
19692494 2009
Prevalence of vitamin K and vitamin D deficiency in patients with hepatobiliary and pancreatic disorders. 54 61
19854384 2009
Prevalence of subclinical vitamin K deficiency in cholestatic liver disease. 61 54
19502999 2009
Coagulation meets calcification: the vitamin K system. 54 61
19363777 2009
Extremes in vitamin K status of bone are related to bone ultrasound properties in children with juvenile idiopathic arthritis. 61 54
18578975 2008
The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. 61 54
18401181 2008
Coagulopathy in liver disease. 61 54
18221607 2007
Justifying the clinical use of fresh frozen plasma - an audit. 61 54
17462177 2007
Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. 61 54
16807654 2006
A case of spontaneous regression of hepatocellular carcinoma with multiple lung metastases. 54 61
16715676 2006
Role of vitamin K2 in the treatment of postmenopausal osteoporosis. 54 61
18690918 2006
Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. 61 54
16425352 2005
Biliary lithiasis in early pregnancy and abnormal development of facial and distal limb bones (Binder syndrome): a possible role for vitamin K deficiency. 61 54
15751048 2005
Prevalence and clinical associations of prolonged prothrombin time in adult untreated coeliac disease. 61 54
15075998 2004
Effects of vitamin K2 on osteoporosis. 61 54
15320745 2004
Echis time, under-carboxylated prothrombin and vitamin K status in intensive care patients. 61 54
14641145 2003
Vitamin K and bone health. 54 61
15018483 2003
Dietary phylloquinone depletion and repletion in older women. 54 61
12888638 2003
Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. 61 54
11994567 2002
Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. 61 54
11846334 2001
Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. 61 54
11410932 2001
Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? 54 61
11247890 2001
Vitamin K deficiency in diarrhoea. 61 54
11338219 2001
Are breast-fed infants vitamin K deficient? 61 54
11787707 2001
Use of oral anticoagulants in older patients. 54 61
10939307 2000
Severe acquired vitamin K deficiency: a hypothesis for rapid response to therapy. 61 54
10870812 2000
Systemic causes of excessive uterine bleeding. 61 54
10513767 1999
Bioavailability of phylloquinone from an intravenous lipid emulsion. 54 61
9537619 1998
[How do we manage the hemorrhagic risk on hypovitaminosis K and treatments with antivitamin K]. 54 61
9750673 1998
Plasma vitamin K1 level is decreased in primary biliary cirrhosis. 54 61
9362192 1997
Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements. 54 61
8989344 1997
The effect of combined antenatal vitamin K and phenobarbital therapy on umbilical blood coagulation studies in infants less than 34 weeks' gestation. 54 61
7501353 1995
[Intrahepatic cholestasis in pregnancy. The hepatologist's point of view]. 54 61
8228018 1993
Vitamin K deficiency. 61 54
7886607 1993
Evidence of vitamin K deficiency in cord blood. 54 61
7886551 1993
Hemolytic uremic syndrome complicated by vitamin K deficiency. 61 54
2069228 1991
Prediction of vitamin K response using the Echis time and Echis-prothrombin time ratio. 54 61
2096486 1990
Chemical modification of gamma-carboxyglutamic acid residues in prothrombin elicits a conformation similar to that of abnormal (des-gamma-carboxy)prothrombin. 54 61
2277030 1990
Helicobacter pylori antibiotic eradication coupled with a chemically defined diet in INS-GAS mice triggers dysbiosis and vitamin K deficiency resulting in gastric hemorrhage. 61
31955643 2020
Cortical vein thrombosis in an infant with delayed vitamin K deficiency bleeding. 61
32491261 2020
Vitamin K Status in Adherent and Non-Adherent Patients with Phenylketonuria: A Cross-Sectional Study. 61
32545860 2020
Piperacillin/tazobactam-induced coagulopathy in a patient through a vitamin K-dependent mechanism. 61
32554527 2020
Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction? 61
32471179 2020
Recurrent Intracranial Bleed in 3 Siblings: Short of a Shot of Vitamin K! 61
32404684 2020
Development, Optimization, and Comparison of Different Sample Pre-Treatments for Simultaneous Determination of Vitamin E and Vitamin K in Vegetables. 61
32481534 2020
An Unusual Presentation of Hemorrhagic Disease in an Infant: A Probable Case of Abetalipoproteinemia. 61
32433446 2020
Current Therapy in CKD Patients Can Affect Vitamin K Status. 61
32486167 2020

Variations for Vitamin K Deficiency Bleeding

Expression for Vitamin K Deficiency Bleeding

Search GEO for disease gene expression data for Vitamin K Deficiency Bleeding.

Pathways for Vitamin K Deficiency Bleeding

Pathways related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
13.48 PROS1 GGCX GAS6 F9 F8 F7
Show member pathways
13.05 SERPINC1 PROS1 GAS6 F9 F8 F7
Show member pathways
12.59 SERPINC1 PROS1 F9 F8 F7 F3
Show member pathways
5 11.86 SERPINC1 PROS1 F9 F8 F7 F3
Show member pathways
11.53 PROS1 GGCX GAS6 F9 F7 F2
Show member pathways
8 10.58 PTH BGLAP

GO Terms for Vitamin K Deficiency Bleeding

Cellular components related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10 SERPINC1 PTH PROS1 GAS6 F9 F8
2 extracellular region GO:0005576 9.93 SERPINC1 PTH PROS1 MGP GAS6 F9
3 collagen-containing extracellular matrix GO:0062023 9.8 SERPINC1 MGP F9 F7 F3 F2
4 blood microparticle GO:0072562 9.61 SERPINC1 PROS1 F2
5 platelet alpha granule lumen GO:0031093 9.58 PROS1 GAS6 F8
6 Golgi lumen GO:0005796 9.43 PROS1 GAS6 F9 F7 F2 BGLAP
7 serine-type peptidase complex GO:1905286 9.37 F7 F3
8 endoplasmic reticulum lumen GO:0005788 9.23 SERPINC1 GAS6 F9 F8 F7 F2

Biological processes related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.8 SERPINC1 GAS6 F2 AFP
2 response to organic cyclic compound GO:0014070 9.73 VKORC1 F7 BGLAP
3 platelet degranulation GO:0002576 9.72 PROS1 GAS6 F8
4 ER to Golgi vesicle-mediated transport GO:0006888 9.7 PROS1 GAS6 F9 F8 F7 F2
5 response to nutrient levels GO:0031667 9.69 PTH F7 BGLAP
6 regulation of bone mineralization GO:0030500 9.58 MGP BGLAP
7 fibrinolysis GO:0042730 9.58 PROS1 F2
8 response to vitamin D GO:0033280 9.57 PTH BGLAP
9 positive regulation of blood coagulation GO:0030194 9.54 F7 F2
10 blood coagulation, intrinsic pathway GO:0007597 9.54 F9 F8 F2
11 positive regulation of positive chemotaxis GO:0050927 9.52 F7 F3
12 regulation of blood coagulation GO:0030193 9.5 VKORC1 SERPINC1 F2
13 hemostasis GO:0007599 9.5 SERPINC1 PROS1 F9 F8 F7 F3
14 vitamin K metabolic process GO:0042373 9.48 VKORC1L1 VKORC1
15 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.46 F7 F3
16 blood coagulation, extrinsic pathway GO:0007598 9.43 F7 F3
17 peptidyl-glutamic acid carboxylation GO:0017187 9.43 VKORC1L1 VKORC1 GGCX
18 response to vitamin K GO:0032571 9.4 F7 BGLAP
19 blood coagulation GO:0007596 9.32 VKORC1 SERPINC1 PROS1 GGCX GAS6 F9

Molecular functions related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.56 F9 F7 F3 F2
2 serine-type peptidase activity GO:0008236 9.54 F9 F7 F2
3 quinone binding GO:0048038 9.32 VKORC1L1 VKORC1
4 calcium ion binding GO:0005509 9.17 PROS1 MGP GAS6 F9 F7 F2
5 vitamin-K-epoxide reductase (warfarin-sensitive) activity GO:0047057 9.16 VKORC1L1 VKORC1
6 structural constituent of bone GO:0008147 8.96 MGP BGLAP

Sources for Vitamin K Deficiency Bleeding

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....